Compare KRSA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRSA | CMMB |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 20.5M |
| IPO Year | N/A | 2023 |
| Metric | KRSA | CMMB |
|---|---|---|
| Price | $33.93 | $2.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | N/A | ★ 122.5K |
| Earning Date | N/A | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $65.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.35 |
| 52 Week High | N/A | $3.55 |
| Indicator | KRSA | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.46 |
| Support Level | N/A | $1.47 |
| Resistance Level | N/A | $2.92 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 21.86 |
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.